Comorbidity and osteoporotic fracture: approach through predictive modeling techniques using the OSTEOMED registry.
María Begoña Coco MartínLuis Leal-VegaJosé Antonio Blázquez CabreraAmalia NavarroMaría Jesús MoroFrancisca Arranz GarcíaMaría José AmérigoManuel Sosa HenríquezMaría Ángeles VázquezMaría José MontoyaManuel Díaz CurielJosé Manuel OlmosJosé Luis Pérez Castrillónnull nullPublished in: Aging clinical and experimental research (2022)
In general, sex, age and the number of comorbidities did not influence the likelihood that a given anti-osteoporotic treatment improved the risk of incident fragility fractures after 1 year, but this appeared to increase when patients had been treated with risedronate, strontium or teriparatide. The two models used classified patients similarly, but predicted differently in terms of the probability of improvement, with logistic regression being the better fit.